Dr. Jagadeesh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
Taussig Cancer Institute
Cleveland, OH 44149Phone+1 216-444-0857
Education & Training
- UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2009 - 2012
- UMass Chan Medical SchoolResidency, Internal Medicine, 2005 - 2008
- University of Massachusetts Medical SchoolInternship, Transitional Year, 2004 - 2005
- J.J.M. Medical CollegeClass of 1996
Certifications & Licensure
- OH State Medical License 2012 - 2026
- MA State Medical License 2008 - 2012
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
- Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2015 Jan 12
- Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) Start of enrollment: 2017 Apr 01
Publications & Presentations
PubMed
- 8 citationsOutcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow...Hemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, Hassan B Alkhateeb, Susan Bal
Transplantation and Cellular Therapy. 2022-04-01 - 48 citationsBurkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centersAndrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim
Blood. 2021-01-21 - 52 citationsPirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, Paolo Ghia, Krish Patel
The New England Journal of Medicine. 2023-07-06
Journal Articles
- Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell TransplantationDeepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
Abstracts/Posters
- Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary EraDeepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, ElotuzumabDeepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat AnalysisDeepa Jagadeesh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.2019 ASCO Annual Meeting - 6/1/2019
- Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Stark County Woman Shares Story of Battle with Rare Cancer to Give Others HopeFebruary 29th, 2020
- Don’t Miss These Cleveland Clinic Cancer Center Presentations at the 2019 ASCO Annual MeetingMay 30th, 2019
- R-EPOCH May Extend Survival in Patients with Rare Forms of Diffuse Large B-cell LymphomaMarch 11th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: